Co-Founder and CEO
Mr. Moradi is a successful entrepreneur, having founded or been a principal in several Nanotech and biopharma startups. Mike was a co-founder and CEO of an ocular pharmaceutical company and specialty Contract Research Organization (CRO), which was #264 fastest growing private company in the 2009 Inc. 500. He co-founded Southwest Nanotechnologies (“SWeNT”), a world-leading manufacturer of carbon nanotubes, and Nanopolaris (now Unidym), which was acquired in 2011 y a publicly traded South Korean company for $145MM.
Dr. Ananth Annapragada, Ph.D.
Co-Founder and Chief Scientist
Dr. Ananth Annapragada is Professor of Radiology, and Director of Basic Research in the Edward B. Singleton Department of Pediatric Radiology, at Texas Children’s Hospital. Previously, he was the Robert Graham Professor of Entrepreneurial Biomedical Informatics and Bioengineering at the School of Biomedical Informatics at the University of Texas, Health Sciences Center at Houston. He holds additional positions at the Graduate School of Biomedical Sciences, the Keck Institute for Computational and Structural Biology, The University of Houston, Rice University and the University of Texas at Austin.
Chris A. Rhodes
Ph.D. Co-Founder and Chief Technology Officer
Dr. Rhodes is a pharmaceutical technologist with experience in combination product development including formulations and devices for pulmonary inhalation aerosol, nasal spray, transdermal patch, sustained release injection, and oral and ocular delivery systems for biopharmaceutical products and small molecules. He has played a key role in the development of the commercial products, Byetta (exenatide injection, FDA 2005), Lusedra (propofol prodrug, FDA 2008), Bydureon (exenatide extended-release for injectable suspension, FDA 2012), Myalept (metreleptin for severe lypodystrophy, FDA 2014), and Afrezza (insulin inhalation powder, FDA under review 2014).
Dr. Rhodes has been responsible for product development including drug delivery R&D, formulation and process development, clinical supply and manufacturing, analytical and bioanalytical chemistry in companies including SKS Ocular, Amylin Pharmaceuticals, Guilford Pharmaceuticals, and Mannkind Pharmaceuticals.
In addition to leading technical functions, he has also been drug development team leader for drug delivery system and molecule development programs translating them from research through clinical proof-of-concept and readying them for commercialization.
Dr. Rhodes earned his Doctorate degree in physical organic chemistry from UCLA and completed his training with a Post Doctoral position at Yale University. He has a Bachelors degree in chemistry from New York University.